S-1: Cingulate Inc. Files for Resale of 2 Million Shares of Common Stock by Lincoln Park Capital

Cingulate Inc. has filed a registration statement for the resale of up to 2,000,000 shares of its common stock by Lincoln Park Capital Fund, LLC.

Summary

• Cingulate Inc. has filed a Form S-1 registration statement with the SEC to register the resale of up to 2,000,000 shares of its common stock by Lincoln Park Capital Fund, LLC.
• These shares may be issued and sold to Lincoln Park under a purchase agreement dated April 24, 2023.
• Cingulate may receive proceeds of up to $11,395,028.72 from the sale of these shares to Lincoln Park.
• Lincoln Park may sell the shares in a number of different ways and at varying prices.
• The last reported sale price of Cingulate's common stock on Nasdaq on May 16, 2024, was $0.79 per share.
• As of May 14, 2024, there were 6,227,577 shares of common stock issued and outstanding.
• If all 2,000,000 shares are issued, they would represent approximately 24% of the total outstanding shares.

Sentiment

Score: 5

Explanation: The document is primarily factual and descriptive, outlining the terms of the share resale agreement. While it highlights potential benefits like access to capital, it also acknowledges risks such as dilution. The sentiment is neutral overall.

Positives

• Cingulate Inc. has access to additional capital through the purchase agreement with Lincoln Park Capital Fund, LLC.
• The company retains control over the timing and amount of sales of common stock to Lincoln Park.
• The purchase agreement can be terminated by Cingulate at any time without penalty.

Negatives

• The sale of common stock to Lincoln Park may cause dilution to existing stockholders.
• The market price of Cingulate's common stock could decrease due to the sale of shares by Lincoln Park.
• The company's management has broad discretion over the use of proceeds from the sale of shares to Lincoln Park.
• The company's independent auditor has raised substantial doubt about the entity's ability to continue as a going concern.

Risks

• Investment in Cingulate's securities involves a high degree of risk.
• The company's lack of operating history and need for additional capital pose risks.
• The company's ability to regain and maintain compliance with Nasdaq listing requirements is uncertain.
• The company's plans to develop and commercialize product candidates may not be successful.
• The company's management will have broad discretion over the use of the net proceeds from our sale of shares of common stock to Lincoln Park, you may not agree with how we use the proceeds and the proceeds may not be invested successfully.

Future Outlook

The company intends to use the proceeds from the sale of shares to Lincoln Park for continued research and development and commercialization activities of CTx-1301, and for working capital, capital expenditures and general corporate purposes, including investing further in research and development efforts.

Industry Context

The company is targeting the ADHD treatment market, which is a large and growing market with significant unmet needs. The company's product candidates are designed to address the key shortcomings of currently approved stimulant therapies.

Comparison to Industry Standards

• The document mentions that extended-release dosage forms of stimulant medications are most frequently deployed as the first-line treatment for ADHD and constitute approximately $16 billion of the overall ADHD market spend and accounting for 54% of all stimulant prescriptions.
• The document states that up to 60% of ADHD patients use a booster dose in conjunction with their primary medication.

Stakeholder Impact

• Existing stockholders may experience dilution of their ownership interest.
• The market price of Cingulate's common stock could be affected by the sale of shares by Lincoln Park.
• The company's ability to fund its research and development programs could be enhanced by the proceeds from the sale of shares to Lincoln Park.

Next Steps

• The SEC must declare the registration statement effective.
• Lincoln Park may then begin reselling the shares of common stock.
• Cingulate Inc. may, at its discretion, direct Lincoln Park to purchase shares of common stock from time to time over the 36-month period commencing on the date that the registration statement is declared effective.

Key Dates

Keywords

common stock, Lincoln Park Capital, resale, registration statement, Cingulate Inc., shares, purchase agreement, securities